A drug, originally used to treat kidney cancer, may prove to be effective in delaying the relapse of ovarian cancer, a clinical study recently revealed. About 70 percent of patients with advanced ovarian cancer experience a relapse following surgery and chemotherapy and need to resume aggressive treatments. The deadly disease's cure rate is just 20 to 25 percent. German researchers found that the GlaxoSmithKlein drug pazopanib (Votrient) extended the median ...Sunday, 2 June 2013
Ovarian Cancer Relapse Delayed, Thanks to a New Drug
A drug, originally used to treat kidney cancer, may prove to be effective in delaying the relapse of ovarian cancer, a clinical study recently revealed. About 70 percent of patients with advanced ovarian cancer experience a relapse following surgery and chemotherapy and need to resume aggressive treatments. The deadly disease's cure rate is just 20 to 25 percent. German researchers found that the GlaxoSmithKlein drug pazopanib (Votrient) extended the median ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment